Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood.2025028985
Abstract: Aberrant activation of BCL11B ("BCL11B-a") defines a subtype of lineage ambiguous leukemias with T-lymphoid and myeloid features, co-occurring activating FLT3 mutations, and a stem/progenitor immunophenotype and gene expression profile. As with other lineage ambiguous leukemias,… read more here.
Keywords: lineage ambiguous; preclinical models; bcl11b; venetoclax plus ... See more keywords